Daiichi Sankyo Company (4568-TO)

FierceBiotech  Aug 7  Comment 
Daiichi Sankyo, Japan's second-largest pharma outfit, has agreed to pay up to $650 million to get its hands on some hydrocodone combo medications, striking a deal with Charleston Laboratories with hopes of cashing in on the demand for pain pills.
Forbes  Jul 14  Comment 
Once again the FDA has reached a conclusion that is directly opposed by some of its own scientists.  Last month the FDA affirmed the safety of olmesartan, a popular blood pressure lowering drug (sold as Benicar and other names). But that...
Motley Fool  Jul 7  Comment 
Portola shares flounder despite the company announcing another collaboration with Daiichi Sankyo. Find out what could have upset investors.
StreetInsider.com  Jul 7  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Portola+Pharma+%28PTLA%29%2C+Daiichi+Sankyo+Enter+Second+Clincial+Collaboration+for+Andexanet+Alfa/9641858.html for the full story.
FiercePharma  Jun 25  Comment 
After four years of sifting data, the FDA says it found "no clear evidence" that Daiichi Sankyo's blockbuster blood pressure drug increased the risk of heart attack. But the agency will require new safety-related data on Benicar's official label.
The Economic Times  Apr 24  Comment 
George Nakayama asked ‘talented’ executives in Ranbaxy Labs to not unduly worry about their prospects in the backdrop of the company getting acquired by Sun Pharma.
FiercePharma  Apr 11  Comment 
Daiichi Sankyo today released its road map for the $3.2 all-stock Ranbaxy deal with Sun Pharmaceutical and the mile markers it sees to completion. It also provides some idea for drugmakers with products facing Ranbaxy generics of how quickly its...
Japan Today  Apr 7  Comment 
Daiichi Sankyo Co Ltd said on Monday that Sun Pharmaceutical Industries Ltd will buy its Indian unit Ranbaxy Laboratories Ltd, creating the world's fifth-largest speciality generics company. Daiichi Sankyo said in a statement that it agrees to...
Financial Times  Feb 2  Comment 
Questions remain about why Daiichi Sankyo, the Japanese owner of the Indian drugmaker, is still struggling to improve quality after five years

You may also be interested in articles related to Daiichi Sankyo Company (4568-TO):
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki